Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Am Acad Child Adolesc Psychiatry ; 54(12): 991-8, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26598474

RESUMO

OBJECTIVE: To evaluate the continued effect of a sequential treatment strategy (fluoxetine followed by continued medication plus relapse prevention cognitive-behavioral therapy [RP-CBT]) on relapse prevention beyond the treatment phase. METHOD: Youth (aged 8-17 years) with major depressive disorder (MDD) were treated with fluoxetine for 6 weeks. Responders (≥50% reduction on the Children's Depression Rating Scale-Revised [CDRS-R]) were randomized to continued medication management alone (MM) or continued medication management plus RP-CBT (MM+CBT) for an additional 6 months. Long-term follow-up assessments were conducted at weeks 52 and 78. RESULTS: Of 144 youth randomized to MM (n = 69) or MM+CBT (n = 75), 67% had at least 1 follow-up assessment, with equal rates in the 2 groups. Remission rates were high, although most had remitted during the 30-week treatment period. Only 6 additional participants remitted during long-term follow-up, and there were no differences on time to remission between MM+CBT and MM. The MM+CBT group had a significantly lower risk of relapse than the MM group throughout the 78-week follow-up period (hazard ratio = 0.467, 95% CI = 0.264 to 0.823; χ(2) = 6.852, p = .009). The estimated probability of relapse during the 78-week period was lower with MM+CBT than MM only (36% versus 62%). Mean time to relapse was also significantly longer with MM+CBT compared to MM alone by approximately 3 months (p = .007). CONCLUSION: The addition of RP-CBT after acute response to medication management had a continued effect on reducing risk of relapse even after the end of treatment. Clinical trial registration information-Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse; http://clinicaltrials.gov/; NCT00612313.


Assuntos
Terapia Cognitivo-Comportamental , Transtorno Depressivo Maior/terapia , Fluoxetina/uso terapêutico , Prevenção Secundária/métodos , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Adolescente , Criança , Cognição , Terapia Combinada , Feminino , Seguimentos , Humanos , Masculino , Modelos de Riscos Proporcionais , Escalas de Graduação Psiquiátrica , Recidiva , Indução de Remissão , Fatores de Risco , Índice de Gravidade de Doença , Método Simples-Cego , Resultado do Tratamento
2.
J Clin Invest ; 123(11): 4706-13, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24216484

RESUMO

Anorexia nervosa and bulimia nervosa are common and severe eating disorders (EDs) of unknown etiology. Although genetic factors have been implicated in the psychopathology of EDs, a clear biological pathway has not been delineated. DNA from two large families affected by EDs was collected, and mutations segregating with illness were identified by whole-genome sequencing following linkage mapping or by whole-exome sequencing. In the first family, analysis of twenty members across three generations identified a rare missense mutation in the estrogen-related receptor α (ESRRA) gene that segregated with illness. In the second family, analysis of eight members across four generations identified a missense mutation in the histone deacetylase 4 (HDAC4) gene that segregated with illness. ESRRA and HDAC4 were determined to interact both in vitro in HeLa cells and in vivo in mouse cortex. Transcriptional analysis revealed that HDAC4 potently represses the expression of known ESRRA-induced target genes. Biochemical analysis of candidate mutations revealed that the identified ESRRA mutation decreased its transcriptional activity, while the HDAC4 mutation increased transcriptional repression of ESRRA. Our findings suggest that mutations that result in decreased ESRRA activity increase the risk of developing EDs.


Assuntos
Transtornos da Alimentação e da Ingestão de Alimentos/genética , Histona Desacetilases/genética , Mutação de Sentido Incorreto , Receptores de Estrogênio/genética , Proteínas Repressoras/genética , Sequência de Aminoácidos , Animais , Anorexia Nervosa/genética , Anorexia Nervosa/metabolismo , Bulimia Nervosa/genética , Bulimia Nervosa/metabolismo , Córtex Cerebral/metabolismo , Transtornos da Alimentação e da Ingestão de Alimentos/metabolismo , Feminino , Predisposição Genética para Doença , Células HeLa , Histona Desacetilases/metabolismo , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Dados de Sequência Molecular , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Linhagem , Receptores de Estrogênio/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Proteínas Repressoras/metabolismo , Homologia de Sequência de Aminoácidos , Transcrição Gênica , Receptor ERRalfa Relacionado ao Estrogênio
3.
J Atten Disord ; 14(1): 86-94, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19805621

RESUMO

OBJECTIVE: The article discusses a feasibility study conducted to examine whether Pay Attention!, an intervention training sustained, selective, alternating, and divided attention, could be utilized in a clinical setting with children diagnosed with ADHD, and whether children who received the intervention made attention and executive functioning gains. METHOD: After a diagnostic and baseline evaluation, 23 school-aged children with ADHD participate in up to 16 sessions of Pay Attention! and the outcomes are evaluated. RESULTS: Results show the intervention is feasible to administer and acceptable to participants. Parents and clinicians rate fewer ADHD symptoms following the intervention and report improvements in executive function. Child performance on neuropsychological tests showed improvements in fluid reasoning and cognitive flexibility and working memory. CONCLUSION: The findings suggest that a randomized clinical trial of Pay Attention! is warranted to investigate its viability as a treatment for attention and executive functioning deficits in ADHD.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/terapia , Terapia Comportamental , Função Executiva , Adolescente , Atenção , Criança , Feminino , Humanos , Masculino , Testes Neuropsicológicos , Seleção de Pacientes , Resultado do Tratamento
4.
J Am Acad Child Adolesc Psychiatry ; 43(6): 761-9, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15167093

RESUMO

OBJECTIVE: To quantify circadian rhythms in rest-activity cycles in depressed children and adolescents. METHOD: Rest-activity cycles were evaluated by actigraphy over five consecutive 24-hour periods in 100 children and adolescents, including 59 outpatients with major depressive disorder (MDD) and 41 healthy normal controls. Total activity, total light exposure, and time spent in light at more than 1,000 lux were averaged over the recording period for each participant. Time series analysis was used to determine the amplitude and period length of circadian rhythms in rest-activity. RESULTS: Overall, adolescents with MDD had lower activity levels, damped circadian amplitude, and lower light exposure and spent less time in bright light than healthy controls. Among children, those with MDD showed lower light exposure and spent less time in bright light, but only depressed girls showed damped circadian amplitude. The sex differences were substantially greater in the MDD group than in the normal control group. CONCLUSIONS: These results confirm damped circadian rhythms in children and adolescents with MDD and highlight the influence of gender and age on these measures.


Assuntos
Ciclos de Atividade , Transtorno Depressivo/fisiopatologia , Adolescente , Distribuição por Idade , Análise de Variância , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Estudos de Casos e Controles , Criança , Comorbidade , Transtorno Depressivo/epidemiologia , Feminino , Humanos , Masculino , Fotoperíodo , Distribuição por Sexo , Estados Unidos/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...